SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The ...
Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial ...
Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...
The Structural Heart Program team at McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth) is among the first in the country to investigate the safety and ...
Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still ...
MADRID--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis ...
Fri, February 6, 2026 at 1:15 PM UTC Edwards delivered $1.55 billion in Q3 2025 revenue, beating estimates by $50 million. The company's TAVR franchise continues dominating a market Edwards helped ...
SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results